Jefferies analyst Maury Raycroft lowered the firm’s price target on Valneva (VALN) to $14 from $18 and keeps a Buy rating on the shares after the FDA suspended the Ixchiq biologics license application based on four new serious adverse events seen outside of the U.S. The firm, which thinks there is some potential risk for ex-U.S. regulators to change their stance on Ixchiq licensure, adds that Ixchiq is “not a major revenue driver” in the near term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Valneva announces U.S. FDA’s decision to suspend license of IXCHIQ
- Valneva Faces FDA Suspension of Chikungunya Vaccine License
- Valneva SE (ADR) trading halted, news pending
- Valneva’s Promising Future: Buy Rating Backed by VLA15 Vaccine and Robust Portfolio
- Valneva assumed with a Buy at H.C. Wainwright